Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...
The Bulldogs’ defensive signal-caller on the field from 2025 is now set to test the waters at the professional level.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback